dopetalk does not endorse any advertised product nor does it accept any liability for it's use or misuse

This website has run out of funding so feel free to contribute if you can afford it (see footer)

Author Topic: RCT of Dexamphetamine maint. for the treatment of Methamphetamine dependence  (Read 1223 times)

Offline Chip (OP)

  • Server Admin
  • Hero Member
  • *****
  • Administrator
  • *****
  • Join Date: Dec 2014
  • Location: Australia
  • Posts: 6641
  • Reputation Power: 0
  • Chip has hidden their reputation power
  • Gender: Male
  • Last Login:Today at 10:21:43 AM
  • Deeply Confused Learner
  • Profession: IT Engineer
source: https://www.tni.org/files/publication-downloads/randomized-trial-dexamphetamine.pdf

Note: these are just excerpts only. Take the source pink for the full article. I have been trying to find someone to prescribe me Dex. for my ADHD (I was on it years ago and have since been buying therapeutic doses on the street for a little less than 20 years) so I don't have to self medicate with Meth.

Randomized controlled trial of Dexamphetamine maintenance for the treatment of Methamphetamine dependence

ABSTRACT

Aim To investigate the safety and efficacy of once-daily supervised oral administration of sustained-release dexamphetamine in people dependent on methamphetamine. Design Randomized, double-blind, placebo-controlled trial.

Participants Forty-nine methamphetamine-dependent drug users from Drug and Alcohol Services South Australia
(DASSA) clinics. Intervention Participants were assigned randomly to receive up to 110 mg/day sustainedrelease dexamphetamine (n = 23) or placebo (n = 26) for a maximum of 12 weeks, with gradual reduction of the study medication over an additional 4 weeks.

Medication was taken daily under pharmacist supervision.

Measurements Primary outcome measures included treatment retention, measures of methamphetamine consumption (self-report and hair analysis), degree of methamphetamine dependence and severity of methamphetamine withdrawal. Hair samples were analysed for methamphetamine using liquid chromatography-mass spectrometry.
 
Findings Treatment retention was significantly different between groups, with those who received dexamphetamine
remaining in treatment for an average of 86.3 days compared with 48.6 days for those receiving placebo (P = 0.014).

There were significant reductions in self-reported methamphetamine use between baseline and follow-up within each group (P < 0.0001), with a trend to a greater reduction among the dexamphetamine group (P = 0.086).
Based on hair analysis, there was a significant decrease in methamphetamine concentration for both groups (P < 0.0001).

At follow-up, degree of methamphetamine dependence was significantly lower in the dexamphetamine group
(P = 0.042). Dexamphetamine maintenance was not associated with serious adverse events.

Conclusions: The results of this preliminary study have demonstrated that a maintenance pharmacotherapy programme of daily sustained release amphetamine dispensing under pharmacist supervision is both feasible and safe. The increased retention in the dexamphetamine group, together with the general decreases in methamphetamine use, degree of dependence and withdrawal symptom severity, provide preliminary evidence that this may be an efficacious treatment option for methamphetamine dependence.

FINAL CONCLUSIONS

This preliminary study evaluated the efficacy and safety of once-daily sustained-release dexamphetamine administered under supervision using a double-blind, placebocontrolled design. Participants in the dexamphetamine group remained in treatment significantly longer and had a significantly lower degree of methamphetamine dependence at follow-up. A significant difference in methamphetamine use between groups was not demonstrated.

This trial has shown the feasibility of implementing a supervised maintenance pharmacotherapy programme
for methamphetamine users that is acceptable to both clients and clinicians. The results of this study support
further investigation of maintenance pharmacotherapy as an intervention for methamphetamine dependence.
« Last Edit: June 01, 2023, 01:17:35 AM by Chip »
friendly
0
funny
0
informative
0
agree
0
disagree
0
like
0
dislike
0
No reactions
No reactions
No reactions
No reactions
No reactions
No reactions
No reactions
Our Discord Server invitation link is https://discord.gg/jB2qmRrxyD

Tags:
 

Related Topics

  Subject / Started by Replies Last post
1 Replies
8663 Views
Last post January 20, 2015, 07:30:32 AM
by smfadmin
0 Replies
4120 Views
Last post October 03, 2016, 12:16:56 AM
by Chip
0 Replies
4287 Views
Last post May 22, 2018, 04:03:37 AM
by Chip
0 Replies
3879 Views
Last post May 04, 2019, 08:22:56 PM
by Chip
0 Replies
2997 Views
Last post June 01, 2019, 06:29:15 AM
by Chip
0 Replies
3602 Views
Last post August 28, 2019, 08:58:56 AM
by Chip
0 Replies
2730 Views
Last post June 28, 2023, 06:19:03 AM
by Chip
0 Replies
4152 Views
Last post July 31, 2023, 12:24:44 PM
by Chip
0 Replies
4639 Views
Last post August 21, 2023, 02:42:29 PM
by Chip
1 Replies
4214 Views
Last post January 12, 2024, 04:20:10 PM
by Chip


dopetalk does not endorse any advertised product nor does it accept any liability for it's use or misuse





TERMS AND CONDITIONS

In no event will d&u or any person involved in creating, producing, or distributing site information be liable for any direct, indirect, incidental, punitive, special or consequential damages arising out of the use of or inability to use d&u. You agree to indemnify and hold harmless d&u, its domain founders, sponsors, maintainers, server administrators, volunteers and contributors from and against all liability, claims, damages, costs and expenses, including legal fees, that arise directly or indirectly from the use of any part of the d&u site.


TO USE THIS WEBSITE YOU MUST AGREE TO THE TERMS AND CONDITIONS ABOVE


Founded December 2014
SimplePortal 2.3.6 © 2008-2014, SimplePortal